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Pregnancy represents a unique immunological situation. Though paternal antigens
expressed by the conceptus are recognized by the immune system of the mother, the
immune response does not harm the fetus. Progesterone and a progesterone induced
protein; PIBF are important players in re-adjusting the functioning of the maternal immune
system during pregnancy. PIBF expressed by peripheral pregnancy lymphocytes, and
other cell types, participates in the feto-maternal communication, partly, by mediating the
immunological actions of progesterone. Several splice variants of PIBF were identified
with different physiological activity. The full length 90 kD PIBF protein plays a role in
cell cycle regulation, while shorter splice variants are secreted and act as cytokines.
Aberrant production of PIBF isoforms lead to the loss of immune-regulatory functions,
resulting in and pregnancy failure. By up regulating Th2 type cytokine production and
by down-regulating NK activity, PIBF contributes to the altered attitude of the maternal
immune system. Normal pregnancy is characterized by a Th2-dominant cytokine
balance, which is partly due to the action of the smaller PIBF isoforms. These bind to
a novel form of the IL-4 receptor, and induce increased production of IL-3, IL-4, and
IL-10. The communication between the conceptus and the mother is established via
extracellular vesicles (EVs). Pre-implantation embryos produce EVs both in vitro, and in
vivo. PIBF transported by the EVs from the embryo to maternal lymphocytes induces
increased IL-10 production by the latter, this way contributing to the Th2 dominant
immune responses described during pregnancy.
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INTRODUCTION
Fifty per cent of the antigens expressed by the fetus originate from the father. Therefore, they are
recognized as foreign and should be “rejected,” yet in spite of all odds, the maternal immune system
does not attack the fetus.
The immune system of the mother must comply with two conflicting requirements, i.e., while
creating a favorable environment for the developing fetus, it has to be prepared to control possible
emerging infections. By establishing a delicate balance, the foeto-maternal unit is able to satisfy the
interests of both themother and the fetus. Progesterone, and its mediator the progesterone-induced
blocking factor (PIBF) are important players in this process. In addition to its endocrine effects,
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progesterone also acts as an “immunosteroid” (1). Progesterone
induces Th2 differentiation of established T cell clones (2) and
regulates the homing and activity of uterine NK cells (3), among
others, by upregulating HLA-G gene expression (4), which is the
ligand for both NK inhibitory and activating receptors. Many of
the immunological effects of progesterone are mediated by PIBF.
This review aims to give an overview on the diverse roles of
progesterone and PIBF in re-setting the functions of the maternal
immune system, and on extracellular vesicles (EVs) as means
of establishing the communication between the two sides of the
feto-maternal unit.
PROGESTERONE RECEPTORS
The biological activity of progesterone is mediated by genomic
and non-genomic pathways. The former depends on two nuclear
progesterone receptor (PR) isoforms, PRA, and PRB (5, 6).
Both isoforms are the products of the same gene, but their
transcription is controlled by two distinct promoters (7).
Mice lacking PRA are infertile (8, 9), while the PRB
isoform mediates the effects of progesterone on mammary
gland development (10). The reproductive tissue responses to
progesterone depend on the relative expression of the two
isoforms (11). Progesterone can also signal through membrane-
bound PRs or via the MAPK or PI3K/Akt pathway. The latter
entirely bypasses the classical PR pathway, signaling either
through the JNK pathway or by increasing cAMP (12).
Studies on PR knock out mice revealed, that PRs are required
not only for endometrial receptivity and decidualization (13), but
also for establishing an appropriate immune environment in the
endometrium (14) (Figure 1). Several studies using nuclear and
cytosol binding assays and immunohistochemistry—indicate,
that in certain conditions lymphoid cells might express PRs
(15–20).
Peripheral lymphocytes of pregnant women, but not those
of non-pregnant individuals express PRs (21, 22). Earlier we
demonstrated an inverse relationship between progesterone
binding capacity and cytotoxic activity of peripheral human
lymphocytes (23). The cytotoxic activity of pregnancy
FIGURE 1 | The effects of progesterone on endometrial development and on
the immune system in early pregnancy.
lymphocytes was significantly reduced by progesterone at
concentrations comparable to those, present in pregnancy
serum, while 100-fold higher progesterone concentrations were
required to alter the cytotoxic activity of lymphocytes from
non-pregnant individuals (24). These findings already suggested
that pregnancy lymphocytes might contain progesterone binding
sites, which enable them to respond to progesterone.
The number of PR positive cells increases throughout normal
gestation. In women with recurrent miscarriage, or in those,
showing clinical symptoms of threatened pre-term delivery, the
% of PR expressing cells among peripheral lymphocytes, is
significantly lower than in women with uneventful pregnancies
(21, 22). These findings suggest, that the presence of PR positive
lymphocytes is required for a normally progressing pregnancy.
PR expression in peripheral lymphocytes or lymphoid cell
lines has been confirmed by several studies (15–17, 25, 26).
Both classical PR isoforms are present in peripheral blood
NK cells (18), however, PR expression in decidual NK cells is
controversial. Van den Heuvel et al. (3) demonstrated PRs in
murine decidual NK cells, while Henderson et al. (27) failed to
detect of PRs in purified decidual NK cells. Nevertheless, the
majority of decidual NK cells are PIBF positive (28).
Both in vitro and in vivo activation of human non-pregnancy
lymphocytes result in increased PR expression (29, 30). Paternal
leukocyte immunization of women with recurrent miscarriage
also increases the number of PR expressing lymphocytes (31).
These data indicate that PR expression is a characteristic
feature of activated immune cells (Figure 2).
FIGURE 2 | The induction and biological significance of lymphocyte
progesterone receptors. Following recognition of fetal antigens, maternal
lymphocytes become activated and express progesterone receptors (PR). The
presence of PRs enables the cells, to respond to progesterone (P), e.g., by
PIBF production.
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PROGESTERONE-REGULATED GENES
Among the progesterone-regulated genes, the transcription
factors Hox-A10, Hox-A11, and the glican binding protein
galectin-1 (Gal-1) are the most relevant for the feto- maternal
immunological interaction (32). Hox-A10 deficient mice are
characterized by a polyclonal T cell proliferation (33), and
impaired decidual NK cell differentiation (24, 25, 34, 35).
Gal-1 expression in the female reproductive system was
described in the nineties, and recently, many functional aspects of
this lectin during pregnancy have been discovered (36–38). Gal-1
gene expression in the mouse uterine tissues has been shown to
be regulated by ovarian steroids during implantation (39). In line
with this, Than et al. (40) identified an estrogen response element
in the Gal-1 gene.
Altered Gal-1 expression in the placenta has been implicated
in several pregnancy pathologies.
Proteomic studies showed that Gal-1 expression is reduced
in placental villous tissues from patients with spontaneous
miscarriages (41). On the other hand, placental Gal-1 expression
was found to be increased in severe preeclampsia (42) as well as
in chorioamnionitis (43), possibly representing a fetal response
to an exaggerated systemic maternal inflammation.
In pregnant mice, stress-induced Gal-1-deficiency results in
an increased rate of fetal loss, which is corrected by progesterone
exposure. Gal-1 treatment on the other hand, prevents the stress-
induced decrease of progesterone as well as PIBF levels, and
restores the resorption rates to a normal level (44). These data
suggest a cross-regulation between progesterone and Gal-1 at the
foeto-maternal interface.
PIBF is another progesterone-regulated gene. The mouse
PIBF1 gene, is transcribed to 16 different mRNAs, the longest
of which is 3,677 bp long and includes 18 exons. The predicted
protein is a 90 kDa molecule, composed of 756 amino acids (45).
The full-length PIBF protein shows a peri-nuclear localization,
(46) and has been identified as a component of the peri-
centriolar satellite (47), suggesting its role in cell cycle regulation.
Alternative splicing produces several smaller isoforms, which
are localized in the cytoplasm (45) and are accountable for the
immunological effects of PIBF.
In murine pregnancy, embryo resorption as well as term
delivery are associated with the absence or lower expression of the
N terminal PIBF exons, which might have important functional
consequences (48).
The loss of the N-terminal exons results in a significantly
reduced production of the full length protein, and also prevents
the synthesis of the smaller protein isoforms, which act on the
cytokine pattern and NK activity (45).
THE IMMUNO-MODULATING EFFECTS OF
PIBF AND THE MAINTENANCE OF
PREGNANCY
PIBF was first described as a 34 kDa protein produced by
activated pregnancy lymphocytes (30). It has become evident
since, that PIBF might be expressed by various reproductive
tissues as well as malignant tumors (49–51). A human study
illustrated that trophoblast cells in the placenta could express
PIBF proteins of 30, 50, and 90 kDa in first trimester (52).
Several human studies suggest an association between
PIBF levels and the outcome of pregnancy. In a prospective
cohort study attempting to identify early risk factors for
miscarriage, PIBF was one of the factors showing a strong
association with miscarriage risk (53). In normal human
pregnancy, both serum-and urinary PIBF concentrations
increase during gestation, while in women, with miscarriage,
or preterm labor, urinary PIBF levels fail to increase (54).
Preterm birth was predictable by lower than normal pregnancy
PIBF values mesaured at 24–28gestational week (55), but not
at 11–13 weeks of gestation (56), suggesting, that predictive
value of PIBF determination depends on the interval,
between sampling and the onset of labor. In line with this,
progestogen-treatment of women with threatened miscarriage
corrected the initially low PIBF levels, and in parallel, reduced
the miscarriage rate to a similar level of healthy controls
(57).
While the full length PIBF has been shown to regulate
trophoblast and tumor cell invasiveness (58–60), the smaller
isoforms are secreted, bind to the PIBF receptor (39, 61)
and via their cytokine-like functions, play a role in the
materno-fetal relationship, both in animal models and in
humans.
Some of the immunological effects of progesterone, e.g., that
on NK activity and cytokine balance, are mediated by PIBF.
Earlier studies showed that in mice PIBF protects pregnancy
by controlling NK activity (62). Anti-PIBF treatment of pregnant
mice results in increased resorption, which are corrected by
simultaneously neutralizing NK activity with anti-NK antibodies
(62).
Decidual NK cells, are functionally different from their
circulating counterparts. Though decidual NK cells selectively
overexpress perforin and granzymes A and B (41, 63), their
cytotoxic activity is low. In normal pregnancy decidual NK
cells contribute to creating a favorable environment for
placentation, implantation and embryo development (64), yet
they are equipped with cytotoxic molecules, to fight intrauterine
infections (65, 66).
In the day 12 mouse decidua, there is an abundance of
PIBF positive granulated cells. These cells are missing from the
deciduae of alymphoid mice, but when alymphoid mice are
reconstituted of with bone marrow from male BALB/c mice, the
PIBF positive granulated cells re-appear in the decidua. These
data suggest that the PIBF+ cells belong to the lymphoid lineage,
and based on their DBA lectin reactivity, to the group of NK
cells.
PIBF+ NK cells contain perforin, which co-localizes with
PIBF in the cytoplasmic granules. In day 12.5 normal mouse
pregnancy only 54% of the PIBF + decidual NK cells contain
perforin, whereas in PIBF deficient mice of the same gestational
age, not only do most of the PIBF+NK cells disappear, but all of
the remaining ones are perforin positive (28).
This implies that in mice PIBF exerts a pregnancy protective
effect by keeping NK activity under restraint.
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The local mechanism of the protective action of PIBF is less
easily studied in humans, than in animal models. Nevertheless, a
recent study showed that the otherwise scarcely studied decidual
B cells produce PIBF under the effect of IL-33, and that these
PIBF + B cells are missing from the choriodecidual area of
women with pre-term labor (67) (Nature).
In spite of their high perforin content, spontaneous cytotoxic
activity of human decidual NK cells is moderate (68).
Progesterone inhibits human NK cytolytic activity in vitro (19),
and upregulates HLA-G gene expression (4). Because HLA-G is a
ligand for NK inhibitory and activating receptors, upregulation of
HLA-G by progesteronemight be one of the pathways accounting
for the low cytotoxic activity of decidual NK cells.
Decidual NK activity appears to be affected by PIBF. PIBF
inhibits upregulation of perforin expression in activated human
decidual NK cells and prevents degranulation (69, 70).
Though there is no evidence that NK cells directly attack
the trophoblast, recurrent miscarriage is often accompanied by
increased decidual NK activity (71–75), suggesting that this
mechanism might be a factor in the underlying pathology of
repeated pregnancy loss.
It is well-established, that while normally progressing
pregnancies are characterized by a Th2 dominant cytokine
pattern, an excess of Th1-associated cytokines leads to pregnancy
termination (76, 77). In humans, recurrent miscarriages are
associated with a Thl-dominant peripheral cytokine profile (78–
82).
Both progesterone and PIBF play a role in the induction of
the Th2 biased cytokine balance. In the presence of progesterone
resting human peripheral blood T cells differentiate into Th2-like
clones, furthermore, progesterone treatment of Th1-like T cell
clones shifts the cytokine production of these cells toward Th2
(2). Neutralization of endogenous PIBF activity in pregnant mice
by specific anti-PIBF antibody terminates pregnancy, reduces the
synthesis of IL-10, and increases that of IFN-γ (83).
The PIBF receptor is a glycosylphosphatidylinositol (GPI)-
anchored protein, which, for signaling, temporarily associates
with the alpha chain of the IL-4 receptor (39, 61). Engagement
of the PIBF receptor results in immediate STAT6 activation,
whereas, a 24 h incubation with progesterone is needed to
phosphorylate STAT6, indicating, that the effect of progesterone
on Th2 cytokine production is mediated by PIBF (61) (Figure 3).
By signaling via this novel form of the IL-4 receptor (39, 61),
PIBF induces increased production of IL-3, IL-4, and IL-10 by
activated murine lymphocytes (84).
Raghupathy et al. (78, 79) investigated the production of
Th1 and Th2 cytokines by progesterone treated peripheral blood
lymphocytes isolated from women with recurrent miscarriage.
They showed that progestogen induced PIBF production down-
regulates the production of Thl-type cytokines and stimulates
the production of Th2-type cytokines. Furthermore, progestogen
treatment of women with pre-term delivery induces a Th2
dominant cytokine pattern (78, 79).
Taken together, these data suggest, that by up regulating Th2
type cytokine production and by down-regulating NK activity
PIBF affects the immune response in a way, which might have
an impact on the foeto-maternal relationship.
FIGURE 3 | The structure of the PIBF receptor. The receptor for PIBF is a GPI
anchored protein. After PIBF binding the receptor associates with the alpha
chain of the IL-4 receptor. This initiates intracellular signaling, via the Jak/STAT
pathway.
THE PERI-IMPLANTATION EMBRYO
COMMUNICATES WITH THE MATERNAL
IMMUNE SYSTEM VIA EXTRACELLULAR
VESICLES
Earlier studies described a communication between the embryo
and the maternal immune system. Embryo culture media were
shown to exert an immunosuppressive activity (84). In line
with this, incubation of human peripheral lymphocytes with the
culture media of fertilized eggs, but not with follicular fluid
resulted in increased IL-10mRNA expression by the lymphocytes
(85).
These data suggest that embryo derived signals, can influence
the maternal immune response, however, the mechanism of
signal transport has not been thoroughly investigated.
In recent years EVs have received much attention. These
membrane-coated structures may express phosphatidylserine
(PS) in their membrane (86), which reacts with Annexin V.
EVs are categorized by their origin and size (87). Exosomes are
30–100 nm, and originate from internalized endocytic vesicles.
Microvesicles (100 nm−1 µm in diameter), are shed from the
plasma membrane by budding, and apoptotic vesicles (1–5µm
in diameter) are released from cells undergoing apoptosis (88).
All types of cells produce EVs which transport various cargos,
(including proteins, nucleic acids, and lipids) from one cell to the
other. Proteins, e.g., cytokines carried and released by EVs could
initiate signaling pathways, and thus alter the biological functions
of the target cells (89, 90).
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EVs might be considered as candidates for conveying the
information from the embryo to themother. Themessage carried
by EVs has been shown to affect the reproductive process at
different points.
EVs have been demonstrated in mouse oocytes (91) as well as
in the follicular fluid (92–96) and extra villous trophoblast (97).
The tetraspanins CD9 andCD81 expressed by oocyte derived EVs
have been suggested to play a role in sperm-oocyte membrane
fusion (98–100). Follicular fluid exosomes contain miRNAs,
some of them targeting genes that regulate oocyte growth (95)
as well as different pathways of reproduction, and endocrine
functions (94).
EV—mediated interactions between the endometrium and the
blastocyst promote implantation (101). In sheep endometrium,
EV production is controlled by progesterone, and endometrium
derived EVs were shown to reach the embryo, (102).
EVs from a human uterine epithelial cells express the
extracellular matrix metalloprotease inducer (103) which induces
the expression of MMPs, thus EVs might also play a role in
endometrial remodeling (101, 103, 104).
EVs can be produced by virtually all cell types, however it has
been debated, whether a single embryo would be able to produce
a detectable amount of EVs. The more so, because the culture
medium contains serum or serum albumin, both of which could
also be a source of EVs. In a review Tannetta et al. (105) points
out the difficulty of measuring EVs in embryo culture medium.
Now there is evidence, that pre-implantation embryos
produce EVs both in vitro and in vivo (106).
Earlier we showed that spent media of in vitro cultured
human embryos contain a significantly higher number of EVs,
than empty media, and the number of nucleic acid containing
EVs in day 5 human embryo culture media, might serve
as an indicator of embryo competence (106). Other groups
have also reported the presence of EVs in embryo culture
medium. It is now obvious that embryos release EVs, which
are taken up by close by cells (90). Giacomini et al. (107)
characterized HLA-G containing EVs isolated from conditioned
media from in vitro cultured human embryos. EVs were
demonstrated in the culture medium of bovine blastocyst and
the characteristics of these EVs varied depending on embryo
competence (108). Qu et al. (109) showed that the negative effects
of culture media replacement during embryo culture are due
to the loss of embryo derived EVs, and can be corrected by
exosome supplementation. This suggests, that embryo derived
EVs do indeed carry molecules that promote normal embryo
development.
FIGURE 4 | Communication between the embryo and the maternal immune system via extracellular vesicles.
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Embryo-derived EVs might also communicate with the
maternal immune system by presenting antigens (110, 111),
carrying MHC molecules (112–115), or cytokines (116–121).
HLA-G-positive EVs isolated from the plasma from healthy term
pregnant women have been reported to bind to T lymphocytes
(122), and moderately decrease peripheral T lymphocyte STAT3
phosphorylation (122). EVs at the same time can induce pro-
inflammatory cytokines and chemokines in primary macrophage
cultures (123, 124).
EVs bind to CD8+ and–though to a lesser degree to CD4+
lymphocytes-, via the phosphatidylserine—phosphatidylserine
receptor interaction (125). CD4+ and CD8+ cells express similar
numbers of phosphatidylserine receptors, therefore, it is likely,
that in addition to the phosphatidylserine—phosphatidylserine
receptor interaction, other, yet unidentified mechanisms might
also be involved in binding of EVs to CD8+ cells. With immuno-
electron microscopy we identified PIBF in embryo-derived EVs,
and showed that these PIBF containing EVs might affect the
immune response (125).
Incubation of murine spleen cells with embryo-derived EVs,
increased the number of IL-10+ cells among peripheral CD8+
cells, but not in the CD4+ population. IL-10 producing CD8+
T lymphocytes might moderate antigen-induced inflammatory
responses, since these cells have been shown to control influenza
virus induced inflammation in the foet (126), and to prevent liver
damage during chronic hepatitis C virus infection (127).
Pre-treatment of EVs with an anti-PIBF antibody abrogates
the above described effect of the EVs. These data suggest that
PIBF transported by the EVs from the embryo to maternal
lymphocytes might induce increased IL-10 production by the
latter, this way contributing to the Th2 dominant immune
responses described during pregnancy. The finding is in line
with our earlier data, (83) showing increased IL-10 production
of murine spleen cells in the presence of PIBF.
This pathway might have its significance in reproduction.
Because embryo derived EVs transport various molecules, - PIBF,
among others-, it cannot be ruled out, that these structures act as
means of feto-maternal or materno-fetal communication in the
peri-implantation period (Figure 4).
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